INDVIndivior Pharmaceuticals, Inc.
# 24 · $34.47 (-2.43%) · $4.07B · Healthcare
52-week range
High-severity risk signals
The scoring engine flagged these high-severity signals. They are warnings to investigate and are not part of the score.
- Altman Z in distress zone
Market data
- P/E
- 12.18
- 1M
- -4.25%
- 1Y
- +36.35%
- Yield
- —
- RSI
- 41.52
- MACD
- -0.01%
Breakdown
Why
- P/E of 12.2
- earnings growth of 2900.0% (inflated by an unusually low prior year)
- profit margin of 26.7%
- 12-1 momentum return of 42.4%
- EPS vs. estimates: +41.7% on average
Rationale is generated by the scoring engine (English).
Piotroski F-Score
3
3 / 9 checks passed
- roa positive
- ocf positive
- roa improving
- accruals
- leverage decreasing
- liquidity improving
- no dilution
- margin improving
- turnover improving
Altman Z-Score
Risk signals
- Altman Z in distress zoneHigh
Z-Score 1.22 (< 1.81) — financial distress risk per the Altman model
- Negative free cash flowMedium
FCF $-0.1B — burning cash
- Earnings quality (accruals)Medium
operating cash flow below reported net income — profits not backed by cash
- Share dilutionInfo
shares outstanding higher than the previous fiscal year
- Rising leverageInfo
debt/assets higher than the previous fiscal year
Company research
Business Overview Indivior Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on medicines for substance use disorders (SUDs), with core products for opioid use disorder (OUD) including SUBLOCADE (monthly extended‑release buprenorphine injection) and SUBOXONE Film (buprenorphine/naloxone sublingual film), plus OPVEE (nalmefene) nasal spray for opioid overdose reversal. It generates revenue primarily from product sales (predominantly in the U.S., which represented ~85% of net revenue in 2024) through wholesalers/distributors with coverage influenced by third‑party payors. Market Position Indivior is a long-standing addiction-treatment player and a leading branded manufacturer in OUD pharmacotherapy, differentiated by long‑acting injectable treatment (SUBLOCADE) and a recognized branded transmucosal franchise (SUBOXONE). Competitive dynamics are driven by formulary access/rebates, clinician adoption, and the availability of generic and other branded OUD therapies. Key Segments Indivior reports operations primarily by geography, with its principal commercial market in the United States and additional sales in selected rest-of-world markets (e.g., parts of Europe, Canada, Australia) via direct operations and distribution partners.
AI-generated summary based on third-party data; it may contain errors. Not investment advice or a recommendation to invest.
Period: 2021-12-31 → 2025-12-31
A dash (—) means the figure is not available for that period, not that it is zero. Nothing here is estimated or filled in.